Inogen, Inc
8.41-0.12 (-1.41%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · INGN · USD
Key Stats
Market Cap
227.41MP/E (TTM)
-Basic EPS (TTM)
-1.06Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Inogen's Q2 revenue climbed 4.0% y/y to $92.3M, driven by 6.4% higher sales revenue from stronger domestic and international business-to-business demand, while rental revenue dipped 8.6% y/y on lower private-payor reimbursements. Gross margin contracted to 44.8% from 48.1% y/y, pressured by channel mix and semiconductor cost premiums, yet operating loss narrowed to $6.1M from $7.1M y/y as expenses fell 4.8%. YTD revenue rose 4.7% y/y to $174.6M, with net loss shrinking 48.8% to $10.3M; diluted EPS of -$0.40 aligns with 26.1M weighted shares, no anti-dilution noted. Cash stood at $103.7M with $18.7M marketable securities, offset by $12.4M operating cash use; free cash flow not disclosed in the 10-Q. The Yuwell collaboration launched Voxi 5 in June for U.S. long-term care. Medicare reimbursements, at 59% of rentals, expose revenue to policy shifts.
8-K
Inogen lifts 2025 revenue outlook
Inogen reported Q2 2025 revenue of $92.3 million, up 4.0% year-over-year, fueled by robust business-to-business sales growth in domestic and international markets, though offset by softer direct-to-consumer and rental segments. Gross margin dipped to 44.8% amid higher B2B mix, yet operating expenses fell 4.7% to $47.5 million, yielding adjusted EBITDA of $2.1 million and GAAP net loss of $4.2 million. Cash reserves swelled to $123.7 million with no debt. The company raised full-year revenue guidance to $354–$357 million and eyes adjusted EBITDA breakeven, while launching Voxi 5 concentrator and Patient Portal to bolster respiratory care access. Momentum builds, but DTC weakness lingers.
8-K
Inogen appoints key executives
Inogen's board designated Jennifer Yi Boyer as executive and Section 16 officer effective July 28, 2025, recognizing her expanded role in HR and strategic initiatives, with a $430,000 base salary and 50% target bonus. They also appointed Mary Wright as Chief Accounting Officer on the same date, bumping her base to $312,000 and bonus target to 35%, while CFO Michael Bourque retains principal accounting duties. Internal promotions signal steady leadership evolution. No family ties or conflicts noted.
8-K
Inogen boosts equity pool
Inogen's stockholders approved the Amended and Restated 2023 Equity Incentive Plan at the May 14, 2025 annual meeting, adding 750,000 shares to the pool for employee and director incentives. This boosts the total shares available to 2,350,000 plus recycled awards, aiming to attract talent amid competitive pressures. Yet dilution looms for existing holders. Plan effective immediately.
10-Q
Q1 FY2025 results
Inogen posted solid Q1 momentum, with total revenue climbing 5.5% year-over-year to $82.3M, fueled by an 8.5% jump in sales to $68.5M from stronger domestic and international business-to-business demand, while rentals dipped 7.5% to $13.8M on reimbursement mix shifts. Gross margin held steady at 44.2%, but operating loss narrowed sharply to $7.7M from $16.3M, thanks to 38.7% lower R&D and 11.8% reduced sales and marketing expenses. Diluted EPS improved to -$0.25 from -$0.62, matching basic due to net loss anti-dilution effects. Cash swelled to $118.9M after a $27.2M stock issuance to Yuwell, covering a $13.0M Physio-Assist earnout payment; free cash flow wasn't disclosed in the 10-Q. The January collaboration with Yuwell eyes U.S. distribution and China entry. Yet regulatory hurdles for new respiratory devices loom large.
AXGN
AxoGen, Inc.
22.25+4.17
IINN
Inspira Technologies Oxy B.H.N.
1.00-0.05
INMD
InMode Ltd.
14.92-0.35
INSP
Inspire Medical Systems, Inc.
75.17-2.00
IRME
IR-Med Inc.
0.03+0.00
NVNO
enVVeno Medical Corporation
0.72+0.00
PODD
Insulet Corporation
316.17-8.17
RMD
ResMed Inc.
253.62-2.95
RTGN
RETINALGENIX TECHNOLOGIES INC
3.75+0.00
TGEN
Tecogen Inc.
9.48+1.21